| Literature DB >> 24798886 |
Frank Jessen1, Rebecca E Amariglio2, Martin van Boxtel3, Monique Breteler4, Mathieu Ceccaldi5, Gaël Chételat6, Bruno Dubois7, Carole Dufouil8, Kathryn A Ellis9, Wiesje M van der Flier10, Lidia Glodzik11, Argonde C van Harten10, Mony J de Leon11, Pauline McHugh11, Michelle M Mielke12, Jose Luis Molinuevo13, Lisa Mosconi11, Ricardo S Osorio11, Audrey Perrotin6, Ronald C Petersen14, Laura A Rabin15, Lorena Rami13, Barry Reisberg16, Dorene M Rentz2, Perminder S Sachdev17, Vincent de la Sayette6, Andrew J Saykin18, Philip Scheltens10, Melanie B Shulman11, Melissa J Slavin19, Reisa A Sperling2, Robert Stewart20, Olga Uspenskaya21, Bruno Vellas22, Pieter Jelle Visser23, Michael Wagner24.
Abstract
There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.Entities:
Keywords: Alzheimer's disease; Mild cognitive impairment; Preclinical Alzheimer's disease; Prodromal Alzheimer 's disease; Research criteria; Subjective cognitive decline
Mesh：
Year: 2014 PMID： 24798886 PMCID： PMC4317324 DOI： 10.1016/j.jalz.2014.01.001
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566